Effect of topical application of melatonin cream 12.5% on cognitive parameters: A randomized, placebo-controlled, double-blind crossover study in healthy volunteers

References

• Trakatelli M, Ulrich C, del Marmol V, et al. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol. 2007;156:1–7.
   PubMed Web of Science ®Google Scholar
• Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;5:1069–80.
   Web of Science ®Google Scholar
• Little EG, Eide MJ. Update on the current state of melanoma incidence. Dermatol Clin. 2012;3:355–61.
   Web of Science ®Google Scholar
• Yaar M, Gilchrest BA. Cellular and molecular mechanisms of cutaneous aging. J Dermatol Surg Oncol. 1990;10:915–22.
   Google Scholar
• Yaar M, Gilchrest BA. Ageing and photoageing of keratinocytes and melanocytes. Clin Exp Dermatol. 2001;7:583–91.
   Web of Science ®Google Scholar
• Emerit I. Free radicals and aging of the skin. EXS. 1992;62:328–41.
   PubMedGoogle Scholar
• Hadshiew IM, Eller MS, Gilchrest BA. Skin aging and photoaging: the role of DNA damage and repair. Am J Contact Dermat. 2000;1:19–25.
   Google Scholar
• Brash DE. Sunlight and the onset of skin cancer. Trends Genet. 1997;13:410–14.
   PubMed Web of Science ®Google Scholar
• Graells J. The risk and risk factors of a second non-melanoma skin cancer: a study in a Mediterranean population. J Eur Acad Dermatol Venereol. 2004;2:142–7.
   Web of Science ®Google Scholar
• Reiter RJ, Tan DX, Osuna C, et al. Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci. 2000;6:444–58.
   Web of Science ®Google Scholar
• Reiter RJ, Tan DX, Sainz RM, et al. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol. 2002;10:1299–321.
   Web of Science ®Google Scholar
• Mauriz JL, Collado PS, Veneroso C, et al. A review of the molecular aspects of melatonin's anti-inflammatory actions: recent insights and new perspectives. J Pineal Res. 2013;1:1–14.
   Google Scholar
• Tan DX, Reiter RJ, Manchester LC, et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem. 2002;2:181–97.
   PubMedGoogle Scholar
• Bangha E, Elsner P, Kistler GS. Suppression of UV-induced erythema by topical treatment with melatonin (N-acetyl-5-methoxytryptamine). A dose response study. Arch Dermatol Res. 1996;288:522–6.
   PubMed Web of Science ®Google Scholar
• Fischer T, Bangha E, Elsner P, et al. Suppression of UV-induced erythema by topical treatment with melatonin. Influence of the application time point. Biol Signals Recept. 1999;8:132–5.
   PubMedGoogle Scholar
• Dreher F, Denig N, Gabard B, et al. Effect of topical antioxidants on UV-induced erythema formation when administered after exposure. Dermatology. 1999;1:52–5.
   Web of Science ®Google Scholar
• Dreher F, Gabard B, Schwindt DA, et al. Topical melatonin in combination with vitamins E and C protects skin from ultraviolet-induced erythema: a human study in vivo. Br J Dermatol. 1998;2:332–9.
   Google Scholar
• Scheuer C, Pommergaard H, Rosenberg J, et al. Dose dependent sun protective effect of topical melatonin: a randomized, placebo-controlled, double-blind study. J Dermatol Sci. 2015.
   Google Scholar
• Scheuer C, Pommergaard HC, Rosenberg J, et al. Melatonin's protective effect against UV radiation: a systematic review of clinical and experimental studies. Photodermatol Photoimmunol Photomed. 2014;4:180–8.
   Web of Science ®Google Scholar
• Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336:186–95.
   PubMed Web of Science ®Google Scholar
• Zhdanova IV. Melatonin as a hypnotic: pro. Sleep Med Rev. 2005;9:51–65.
   PubMed Web of Science ®Google Scholar
• Zhdanova IV, Wurtman RJ, Regan MM, et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab. 2001;86:4727–30.
   PubMed Web of Science ®Google Scholar
• Cardinali DP, Furio AM, Reyes MP, et al. The use of chronobiotics in the resynchronization of the sleep-wake cycle. Cancer Causes Control. 2006;4:601–9.
   Web of Science ®Google Scholar
• Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev. 2005;9:25–39.
   PubMed Web of Science ®Google Scholar
• Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;8:e1–37.
   Google Scholar
• Pathak MA, Fitzpatrick TB, Greiter F, et al. Preventive treatment of sunburn, dermatoheliosis, and skin cancer with sun-protective agents. Dermatol Gen Med. 1993;4:1689–717.
   Google Scholar
• Dubois DDE. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863–71.
   Google Scholar
• Akerstedt T, Gillberg M. Subjective and objective sleepiness in the active individual. Int J Neurosci. 1990;12:29–37.
   Google Scholar
• Axelrod BN, Meyers JE, Davis JJ. Finger tapping test performance as a measure of performance validity. Clin Neuropsychol. 2014;5:876–88.
   Web of Science ®Google Scholar
• Criswell S, Sterling C, Swisher L, et al. Sensitivity and specificity of the finger tapping task for the detection of psychogenic movement disorders. Parkinsonism Relat Disord. 2010;16:197–201.
   PubMed Web of Science ®Google Scholar
• Prigatano GP, Wong JL. Speed of finger tapping and goal attainment after unilateral cerebral vascular accident. Arch Phys Med Rehabil. 1997;8:847–52.
   Web of Science ®Google Scholar
• de Groot-Driessen D, van de Sande P, van Heugten C. Speed of finger tapping as a predictor of functional outcome after unilateral stroke. Arch Phys Med Rehabil. 2006;1:40–4.
   Web of Science ®Google Scholar
• Peters M. Prolonged practice of a simple motor task by preferred and nonpreffered hands. Percept Mot Skills. 1976;42:447–50.
   PubMed Web of Science ®Google Scholar
• Elsass P. Continuous reaction times in cerebral dysfunction. Acta Neurol Scand. 1986;3:225–46.
   Google Scholar
• Ftouni S, Sletten TL, Howard M, et al. Objective and subjective measures of sleepiness, and their associations with on-road driving events in shift workers. J Sleep Res. 2013;22:58–69.
   PubMed Web of Science ®Google Scholar
• Ingre M, Akerstedt T, Peters B, et al. Subjective sleepiness and accident risk avoiding the ecological fallacy. J Sleep Res. 2006;2:142–8.
   Web of Science ®Google Scholar
• Tzischinsky O, Lavie P. Melatonin possesses time-dependent hypnotic effects. Sleep. 1994;7:638–45.
   Google Scholar
• Barchas J, DaCosta F, Spector S. Acute pharmacology of melatonin. Nature. 1967;5091:919–20.
   Web of Science ®Google Scholar
• Nordlund JJ, Lerner AB. The effects of oral melatonin on skin color and on the release of pituitary hormones. J Clin Endocrinol Metab. 1977;45:768–74.
   PubMed Web of Science ®Google Scholar
• Kucukakin B, Lykkesfeldt J, Nielsen HJ, et al. Utility of melatonin to treat surgical stress after major vascular surgery-a safety study. J Pineal Res. 2008;4:426–31.
   Web of Science ®Google Scholar
• Kucukakin B, Wilhelmsen M, Lykkesfeldt J, et al. No effect of melatonin to modify surgical-stress response after major vascular surgery: a randomised placebo-controlled trial. Eur J Vasc Endovasc Surg. 2010;4:461–7.
   Google Scholar
• Nickkholgh A, Schneider H, Sobirey M, et al. The use of high-dose melatonin in liver resection is safe: first clinical experience. J Pineal Res. 2011;4:381–8.
   Web of Science ®Google Scholar
• Dollins AB, Zhdanova IV, Wurtman RJ, et al. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci USA. 1994;5:1824–8.
   Web of Science ®Google Scholar
• Zhdanova IV, Wurtman RJ, Lynch HJ, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther. 1995;5:552–8.
   Web of Science ®Google Scholar
• Lieberman HR, Waldhauser F, Garfield G, et al. Effects of melatonin on human mood and performance. Brain Res. 1984;2:201–7.
   Web of Science ®Google Scholar
• Naguib M, Samarkandi AH. Premedication with melatonin: a double-blind, placebo-controlled comparison with midazolam. Br J Anaesth. 1999;82:875–80.
   PubMed Web of Science ®Google Scholar
• Arendt J. Melatonin and the Mammalian Pineal Gland. London: Chapmann and Hall, 1995.
   Google Scholar
• Benes L, Claustrat B, Horriere F, et al. Transmucosal, oral controlled-release, and transdermal drug administration in human subjects: a crossover study with melatonin. J Pharm Sci. 1997;10:1115–19.
   Web of Science ®Google Scholar
• Bangha E, Lauth D, Kistler GS, et al. Daytime serum levels of melatonin after topical application onto the human skin. Skin Pharmacol. 1997;56:298–302.
   Google Scholar
• Fischer TW, Greif C, Fluhr JW, et al. Percutaneous penetration of topically applied melatonin in a cream and an alcoholic solution. Skin Pharmacol Physiol. 2004;4:190–4.
   Web of Science ®Google Scholar
• Aeschbach D, Lockyer BJ, Dijk DJ, et al. Use of transdermal melatonin delivery to improve sleep maintenance during daytime. Clin Pharmacol Ther. 2009;4:378–82.
   Web of Science ®Google Scholar
• Acil M, Basgul E, Celiker V, et al. Perioperative effects of melatonin and midazolam premedication on sedation, orientation, anxiety scores and psychomotor performance. Eur J Anaesthesiol. 2004;7:553–7.
   Google Scholar
• Naguib M, Samarkandi AH. The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: a double-blinded, placebo-controlled study. Anesth Analg. 2000;91:473–9.
   PubMed Web of Science ®Google Scholar
• Sjogren P, Olsen AK, Thomsen AB, et al. Neuropsychological performance in cancer patients: the role of oral opioids, pain and performance status. Pain. 2000;3:237–45.
   Web of Science ®Google Scholar
• Sjogren P, Thomsen AB, Olsen AK. Impaired neuropsychological performance in chronic nonmalignant pain patients receiving long-term oral opioid therapy. J Pain Symptom Manage. 2000;2:100–8.
   Web of Science ®Google Scholar
• Kurita GP, de Mattos Pimenta CA, Braga PE, et al. Cognitive function in patients with chronic pain treated with opioids: characteristics and associated factors. Acta Anaesthesiol Scand. 2012;56:1257–66.
   PubMed Web of Science ®Google Scholar
• Jensen ML, Sjogren P, Upton RN, et al. Pharmacokinetic–pharmacodynamic relationships of cognitive and psychomotor effects of intravenous buprenorphine infusion in human volunteers. Basic Clin Pharmacol Toxicol. 2008;1:94–101.
   Web of Science ®Google Scholar
• Anton-Tay F, Diaz JL, Fernandez-Guardiola A. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci I. 1971;15:841–50.
   Google Scholar
• Cramer H, Rudolph J, Consbruch U, et al. On the effects of melatonin on sleep and behavior in man. Adv Biochem Psychopharmacol. 1974;11:187–91.
   PubMedGoogle Scholar
• Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology (Berl). 1990;2:222–6.
   Web of Science ®Google Scholar